TCA
TXG icon

Trifecta Capital Advisors’s 10x Genomics TXG Stock Holding History

Trifecta Capital Advisors’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53.1K Buy
1,385
+1,175
+560% +$30.8K 0.01% 187
2026
Q1 		$4.46K Hold
210
– – ﹤0.01% 247
2025
Q4 		$3.43K Sell
210
-17,130
-99% -$259K ﹤0.01% 249
2025
Q3 		$203K Sell
17,340
-11,860
-41% -$155K 0.03% 106
2025
Q2 		$338K Buy
+29,200
New +$266K 0.06% 82

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Trifecta Capital Advisors's TXG Position: Q2 2026 in Review

Trifecta Capital Advisors increased its 10x Genomics (TXG) stake by 560% in Q2 2026, buying an estimated $30.8K and bringing the position to 1,385 shares worth $53.1K. The position accounts for 0.01% of the portfolio, ranked #187.

Trifecta Capital Advisors first reported a position in TXG in Q2 2025 and has held it in 5 quarters since. The position peaked at $338K in Q2 2025. 392 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Trifecta Capital Advisors held 1,385 shares of 10x Genomics worth $53.1K as of Q2 2026.
  • Trifecta Capital Advisors bought 1,175 10x Genomics shares in Q2 2026, an estimated $30.8K.
  • 10x Genomics made up 0.01% of Trifecta Capital Advisors's portfolio in Q2 2026, its #187 holding.
  • Trifecta Capital Advisors first reported a position in 10x Genomics in Q2 2025 and has held it in 5 quarters since.
  • Trifecta Capital Advisors's 10x Genomics position peaked at $338K in Q2 2025.
  • 392 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Trifecta Capital Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.